Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Magnesium Sulphate Halves Risk Of Eclampsia And Can Save Lives Of Pregnant Women

31.05.2002


Giving magnesium sulphate injections to pregnant women with pre-eclampsia halves the risk of eclampsia developing and can save their lives. This is the conclusion of a major international clinical trial funded by the Medical Research Council (MRC) and published in this week’s The Lancet.



The three-year £2.5 million study, the ‘Magpie’* Trial, was conducted in 33 countries spanning the UK and much of the developing world where eclampsia is the most common cause of death for pregnant women. The trial involved over 10,000 women.

All of the women were suffering from pre-eclampsia (pregnancy-induced high blood pressure, commonly known as toxaemia) which can lead to eclampsia (convulsions) which threatens both the mother’s and the baby’s lives.


In addition to normal medical care, half the women in the trial were randomly assigned to receive an injection of magnesium sulphate, an anticonvulsant drug. The other half was allocated a placebo treatment.

Women allocated magnesium sulphate had a 58% lower risk of eclampsia than those allocated the placebo. Although the treatment did not affect whether or not the baby died, there was evidence that it can reduce the risk of the mother dying. A quarter of women reported minor side effects but there was no evidence of harmful effects to either the mother or baby.

Dr Lelia Duley, an MRC Senior Clinical Fellow and Obstetric Epidemiologist in the Institute of Health Sciences at the University of Oxford, led the research.

She said: “Eclampsia is a devastating condition that can kill both mother and child. Our trial has shown that giving magnesium sulphate injections halves the risk of developing eclampsia for women who already have pre-eclampsia, and it seems likely it also reduces the risk of maternal death. The treatment could save countless lives across the world if it was introduced routinely for pregnant women with pre-eclampsia. And, importantly, it is a very inexpensive treatment, making it especially suitable for use in low income countries.”

Professor Jim Neilson, Professor of Obstetrics and Gynaecology at the University of Liverpool, was one of the clinicians who worked on the trial. He said: “Anticonvulsant drugs have been given to some women with pre-eclampsia for several years but this is the first time that we’ve shown clear benefits for magnesium sulphate treatment through a major research study. These exciting results should now change routine clinical practice across the UK and the world.”

Claire Giles, a woman who suffered pre-eclampsia during her first pregnancy and who took part in the trial, said: “I was really pleased to be part of such an important trial. I developed swelling at 32 weeks which grew progressively more severe until I was finally diagnosed with pre-eclampsia and admitted to hospital at 38 weeks. My baby was delivered by caesarean section and thankfully we both made a complete recovery. Pre-eclampsia is a frightening condition and I really hope that the results of the trial will benefit women like me.”

One in ten pregnant women world-wide suffers from pre-eclampsia, often in their first pregnancy. Currently the only definitive treatment is to deliver the baby early. Once the baby is born the mother’s blood pressure usually returns to normal although the baby will often require intensive medical care due to being born prematurely.

Women seeking further information about pre-eclampsia and eclampsia can call the Action on Pre-eclampsia (APEC) Helpline on 020 8427 4217 (weekdays 10am - 1pm).

The research was funded mainly by the Medical Research Council with support from the Department for International Development, the UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction and the European Commission, DG Research, INCO Programme.

Press Office | alphagalileo

More articles from Health and Medicine:

nachricht Researchers release the brakes on the immune system
18.10.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht Norovirus evades immune system by hiding out in rare gut cells
12.10.2017 | University of Pennsylvania School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

 
Latest News

Electrode materials from the microwave oven

19.10.2017 | Materials Sciences

New material for digital memories of the future

19.10.2017 | Materials Sciences

Physics boosts artificial intelligence methods

19.10.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>